SYNCOM FORMULATIONS (INDIA)
Quarterly Results Analysis [Dec2024]
SYNCOM FORMULATIONS (INDIA) Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹128 Cr | ₹102 Cr | ₹87 Cr | ₹75 Cr | ₹65 Cr | ₹64 Cr | ₹60 Cr | ₹61 Cr |
Expenses | ₹113 Cr | ₹90 Cr | ₹77 Cr | ₹65 Cr | ₹58 Cr | ₹57 Cr | ₹53 Cr | ₹55 Cr |
Operating Income | ₹15 Cr | ₹12 Cr | ₹10 Cr | ₹9 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr |
Other Income | ₹4 Cr | ₹4 Cr | ₹1 Cr | ₹3 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹7 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
Depreciation | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
Profit Before Tax | ₹17 Cr | ₹15 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹6 Cr | ₹10 Cr |
Profit After Tax | ₹13 Cr | ₹11 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹4 Cr | ₹8 Cr |
EPS | ₹0.14 | ₹0.12 | ₹0.08 | ₹0.08 | ₹0.07 | ₹0.07 | ₹0.05 | ₹0.09 |
Industry Peers & Returns | 1W | 1M | 1Y |
SYNCOM FORMULATIONS (INDIA) | -9.7% | -13% | 7.7% |
SUN PHARMACEUTICAL INDUSTRIES | -3% | -8.7% | 4.1% |
DIVIS LABORATORIES | -4.7% | -4.5% | 58.5% |
CIPLA | -4.3% | -3.2% | -3.2% |
TORRENT PHARMACEUTICALS | -3% | -12.3% | 13.8% |
DR REDDYS LABORATORIES | -3% | -6.5% | -12.7% |
MANKIND PHARMA | -1.6% | -8% | 9.4% |
ZYDUS LIFESCIENCES | -1% | -8.1% | -5.9% |
LUPIN | NA | -7.7% | 16.6% |
SYNCOM FORMULATIONS (INDIA) Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 24.65 % |
Y-o-Y | 95.78 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹128 Cr | 24.65 | |
Sep2024 | ₹102 Cr | 17.26 | |
Jun2024 | ₹87 Cr | 17.01 | |
Mar2024 | ₹75 Cr | 14.48 | |
Dec2023 | ₹65 Cr | 2.04 | |
Sep2023 | ₹64 Cr | 6.69 | |
Jun2023 | ₹60 Cr | -1.87 | |
Mar2023 | ₹61 Cr | - |
SYNCOM FORMULATIONS (INDIA) Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 21.12 % |
Y-o-Y | 100.16 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹15 Cr | 21.12 | |
Sep2024 | ₹12 Cr | 16.33 | |
Jun2024 | ₹10 Cr | 10.93 | |
Mar2024 | ₹9 Cr | 28.06 | |
Dec2023 | ₹7 Cr | 14.86 | |
Sep2023 | ₹6 Cr | -0.82 | |
Jun2023 | ₹6 Cr | 8.39 | |
Mar2023 | ₹6 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -2.86 % |
Y-o-Y | 2.21 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 11.55% | -2.86 | |
Sep2024 | 11.89% | -0.75 | |
Jun2024 | 11.98% | -5.22 | |
Mar2024 | 12.64% | 11.86 | |
Dec2023 | 11.3% | 12.55 | |
Sep2023 | 10.04% | -7.04 | |
Jun2023 | 10.8% | 10.54 | |
Mar2023 | 9.77% | - |
SYNCOM FORMULATIONS (INDIA) Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 17.04 % |
Y-o-Y | 85.65 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹13 Cr | 17.04 | |
Sep2024 | ₹11 Cr | 45.53 | |
Jun2024 | ₹8 Cr | 3.11 | |
Mar2024 | ₹7 Cr | 5.71 | |
Dec2023 | ₹7 Cr | 7.54 | |
Sep2023 | ₹7 Cr | 48.13 | |
Jun2023 | ₹4 Cr | -48.11 | |
Mar2023 | ₹8 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -6.17 % |
Y-o-Y | -5.21 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 10.19 % | -6.17 | |
Sep2024 | 10.86 % | 24.11 | |
Jun2024 | 8.75 % | -11.88 | |
Mar2024 | 9.93 % | -7.63 | |
Dec2023 | 10.75 % | 5.39 | |
Sep2023 | 10.2 % | 38.78 | |
Jun2023 | 7.35 % | -47.08 | |
Mar2023 | 13.89 % | - |
SYNCOM FORMULATIONS (INDIA) Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 16.67 % |
Y-o-Y | 100.00 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹0.14 | 16.67 | |
Sep2024 | ₹0.12 | 50.00 | |
Jun2024 | ₹0.08 | 0.00 | |
Mar2024 | ₹0.08 | 14.29 | |
Dec2023 | ₹0.07 | 0.00 | |
Sep2023 | ₹0.07 | 40.00 | |
Jun2023 | ₹0.05 | -44.44 | |
Mar2023 | ₹0.09 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD